Literature DB >> 23237909

The maintenance of epigenetic states by p53: the guardian of the epigenome.

Arnold J Levine1, Benjamin Greenbaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237909      PMCID: PMC3681489          DOI: 10.18632/oncotarget.780

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


× No keyword cloud information.
The functions of the p53 tumor suppressor gene and its protein are to ensure fidelity of cellular replicative processes so as to minimize mutational errors even in the presence of a wide variety of environmental stresses. Among the stresses p53 senses and responds to are DNA damage including telomere erosion, hypoxia, nutrient deprivation, errors in ribosomal biogenesis, abnormal chromosome segregation and even the mutational activation of several diverse oncogenes. Each of these stresses increases the rate of mutagenesis and the frequencies of cancers. When a cell senses a stress, it signals to the p53 protein using a wide variety of protein modifications (phosphorylation, acetylation, methylation), which help to increase the half-life of the p53 protein and activate it as a transcription factor. The p53 protein then rolls out a transcriptional program resulting in cell cycle arrest, senescence, or apoptosis, repairing or eliminating the cell depending upon the cell type, its state of transformation or other environmental factors. That this is an important process is demonstrated by the observations that the p53 gene is the most commonly mutated gene in human cancers and individuals who inherit mutations in this gene develop cancers at a young age [1]. Leonova and Gudkov and their colleagues have just published a paper [2] that adds a number of new observations to this picture. First, p53 keeps several families of repetitive DNA elements transcriptionally silent, presumably by binding to the chromatin associated with these sequences. Indeed, the treatment of cells without p53, but not cells with a wild-type p53, with 5-aza-2'-deoxycytidine, which blocks DNA methylation and alters the chromatin to make it more transcriptionally active, results in a large increase in the rate of transcription of these repetitive DNA elements in a cell. These repetitive RNA species form double-stranded RNAs and increase the frequency of the dinucleotide CpG in RNA species and both these events engage toll-like receptors in the cell and initiate cytokine production including type 1 interferon which can then lead to apoptotic death of the host cells. Both hypomethylation of repetitive cellular DNA and the transcription of repetitive DNA elements have been reported in pancreatic cancers and other carcinomas [3] and the survival of these cancer cells suggests that they have evolved a mechanism to escape p53-interferon mediated cell death. Among the striking observations made in this work is one that has a great deal of support from previous studies; i.e. the absence of wild-type p53 in a cell appears to permit changes in the epigenetic profile of the cell. In other words the p53 protein guards against epigenetic change. Jaenisch and his colleagues [4] first demonstrated that the CRE mediated loss of the DNA methyltransferase gene (Dnmt1) in cells results in a p53 activated apoptosis after the cells undergo several divisions. This suggests that p53 senses epigenetic changes or their consequences and kills cells undergoing such changes. The global loss of imprinting can then lead to widespread tumorigenesis in adult mice [5]. Takahashi and Yamanaka [6] demonstrated that the addition of four transcription factors (c-myc, KLF-4, Oct 4, Sox-2) to fibroblasts in culture results in the epigenetic reprograming of these cells so as to form induced pluripotent stem cells (iPS cells). The process was inefficient (about 0.1% of the cells), took a long time (3 to 4 weeks) and the iPS cells produced tumors when implanted (because of the myc and KLF-4 oncogenes). One could increase the efficiency of this process (up to 80%) and decrease the time it takes to make iPS cells (5 to 6 days) by employing cells that were derived from p53 knock-out mice [7,8]. The presence of wild-type p53 decreases the efficiency and slows the rate of changes during epigenetic reprograming. Indeed p53 knockout mice can have birth defects and these mice have an altered epigenetic methylation of their DNA [8]. In human breast cancers [9] and prostate cancers [10] that contain p53 mutations the transcriptional profiles of those tumors closely resemble embryonic stem cells in contrast to tumors with a wild-type p53 protein. The evidence is accumulating that the p53 protein is the guardian of the genome, the guardian of the epigenome and the guardian of repeated DNA sequences keeping them silent and protecting the cell from “interferon death” One might ask what is the role of the transcripts produced by repetitive DNA elements in the cell in initiating interferon or cytokine death. A number of RNA viruses produce double-stranded RNAs, which can engage Toll-like receptor-3 and initiate the transcription of interferon genes. However, there is a second trigger of Toll- like receptors 7 and 8 by single stranded RNAs some of which derive from DNA sequences with high CpG dinucleotide compositions. The removal of methylation from the CpG dinucleotides in DNA, permitting transcription of that DNA, is in itself a trigger for the Toll-like receptor 9 resulting in a cytokine storm. Influenza viruses that replicate in birds contain a much higher CpG dinucleotide content than the Influenza viruses that replicate in humans [11]. In 1918 a bird Influenza virus infected the human population with a very high CpG dinucleotide frequency. This was the very pathogenic strain that may well have initiated cytokine storms in the population and were highly lethal for their hosts. Indeed RNAs with high CpG dinucleotides have been shown to produce interferon and cytokines in cell culture [12] and the influenza strains that entered the human population in 1918 (the H1N1 strains) have lowered their CpG dinucleotide content over the past 100 years of replication in the human host [13]. Coincident with this change in dinucleotide frequency the pathogenicity of these viruses has declined in human populations. Toll-like receptor 7 appears to mediate this cytokine storm in response to a set of RNAs with high CpG dinucleotide frequencies [13]. Thus the mechanisms of interferon mediated cell death in the absence of p53, as described by Gudkov and his colleagues demonstrate a role for p53 in stabilizing the epigenetic state of a cell, preventing it from changing. Second, in the event p53 function is lost and there are changes in the epigenetic state there is a failsafe, interferon mediated cell death. This is similar to the loss of p53 in cancer cells increasing the concentrations of the DJ-1 protein that is thought to play a role in reducing reactive oxygen species, a function that wild-type p53 commonly is employed to regulate (the Redox potential of a cell) [14]. We are beginning to find selective back up functions for the loss of wild-type p53 in cancer cells. As cancers develop under high mutation rates these back up functions fail and the cancer cells evolve. We will need to understand these processes.
  14 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Stem cell biology meets p53.

Authors:  Anna M Puzio-Kuter; Arnold J Levine
Journal:  Nat Biotechnol       Date:  2009-10       Impact factor: 54.908

3.  Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.

Authors:  David T Ting; Doron Lipson; Suchismita Paul; Brian W Brannigan; Sara Akhavanfard; Erik J Coffman; Gianmarco Contino; Vikram Deshpande; A John Iafrate; Stan Letovsky; Miguel N Rivera; Nabeel Bardeesy; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2011-01-13       Impact factor: 47.728

4.  Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation.

Authors:  L Jackson-Grusby; C Beard; R Possemato; M Tudor; D Fambrough; G Csankovszki; J Dausman; P Lee; C Wilson; E Lander; R Jaenisch
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

5.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

6.  Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.

Authors:  Hideaki Mizuno; Benjamin T Spike; Geoffrey M Wahl; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

7.  Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells.

Authors:  Sonia Jimenez-Baranda; Benjamin Greenbaum; Olivier Manches; Jesse Handler; Raúl Rabadán; Arnold Levine; Nina Bhardwaj
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

8.  Global loss of imprinting leads to widespread tumorigenesis in adult mice.

Authors:  Teresa M Holm; Laurie Jackson-Grusby; Tobias Brambrink; Yasuhiro Yamada; William M Rideout; Rudolf Jaenisch
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

9.  Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune system.

Authors:  Benjamin D Greenbaum; Raul Rabadan; Arnold J Levine
Journal:  PLoS One       Date:  2009-06-18       Impact factor: 3.240

10.  Patterns of evolution and host gene mimicry in influenza and other RNA viruses.

Authors:  Benjamin D Greenbaum; Arnold J Levine; Gyan Bhanot; Raul Rabadan
Journal:  PLoS Pathog       Date:  2008-06-06       Impact factor: 6.823

View more
  15 in total

1.  Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Authors:  Jae-Seok Roe; Chang-Il Hwang; Tim D D Somerville; Joseph P Milazzo; Eun Jung Lee; Brandon Da Silva; Laura Maiorino; Hervé Tiriac; C Megan Young; Koji Miyabayashi; Dea Filippini; Brianna Creighton; Richard A Burkhart; Jonathan M Buscaglia; Edward J Kim; Jean L Grem; Audrey J Lazenby; James A Grunkemeyer; Michael A Hollingsworth; Paul M Grandgenett; Mikala Egeblad; Youngkyu Park; David A Tuveson; Christopher R Vakoc
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

Review 2.  p53: 800 million years of evolution and 40 years of discovery.

Authors:  Arnold J Levine
Journal:  Nat Rev Cancer       Date:  2020-05-13       Impact factor: 60.716

3.  Heritable one-hit events defining cancer prevention?

Authors:  Levy Kopelovich; Brittney Shea-Herbert
Journal:  Cell Cycle       Date:  2013-07-29       Impact factor: 4.534

4.  p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity.

Authors:  Ayala Tovy; Adam Spiro; Ryan McCarthy; Zohar Shipony; Yael Aylon; Kendra Allton; Elena Ainbinder; Noa Furth; Amos Tanay; Michelle Barton; Moshe Oren
Journal:  Genes Dev       Date:  2017-06-12       Impact factor: 11.361

5.  Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.

Authors:  Antoine Tanne; Luciana R Muniz; Anna Puzio-Kuter; Katerina I Leonova; Andrei V Gudkov; David T Ting; Rémi Monasson; Simona Cocco; Arnold J Levine; Nina Bhardwaj; Benjamin D Greenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

6.  Non-Random Selection of Cancer-Causing Mutations in Tissue-Specific Stem Cells Cause Cancer.

Authors:  Arnold J Levine
Journal:  J Clin Oncol Res       Date:  2020-09-22

7.  Cell context dependent p53 genome-wide binding patterns and enrichment at repeats.

Authors:  Krassimira Botcheva; Sean R McCorkle
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

8.  p53 binding to human genome: crowd control navigation in chromatin context.

Authors:  Krassimira Botcheva
Journal:  Front Genet       Date:  2014-12-22       Impact factor: 4.599

Review 9.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 10.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.